Archive for the ‘Nuclear Medicine’ Category

March 1, 2012 | 10:43 am

AREVA Med Launches Oncology Clinical Trial Website

AREVA Med’s new clinical trial website, www.TargetedTrials.com, provides a comprehensive source of information for patients and physicians searching for innovative oncology trials.

Visitors will find information that describes the therapy, abdominal cancers, the clinical trial process and eligibility criteria for the Phase I trial underway at the University of Alabama at Birmingham (UAB). The clinical trial, the first to use lead-212 (212Pb), aims to evaluate a new approach for hard-to-treat cancers such as ovarian, pancreatic, colon, gastric, endometrial, and breast cancer that have spread to the abdominal cavity. With few options available for combating these cancers, AREVA Med hopes that this innovative radioimmunotherapy approach will eventually provide significant benefits to patients with abdominal metastatic cancers.

AREVA Med’s therapy, called ²¹²Pb-TCMC-Trastuzumab, uses a radioisotope attached to a monoclonal antibody. Radioimmunotherapy is a novel approach that destroys cancer cells by combining the accuracy and selectiveness of a monoclonal antibody with a powerful radioisotope. Simply put, the antibody transports and delivers the lead-212 (²¹²Pb) to the cancer cell. Lead-212 is a radioactive isotope with short-range energy that then kills the cancer cell.

This video shows AREVA Med’s radioimmunotherapy in action.

July 15, 2011 | 4:38 pm

AREVA Med Initiates Patient Recruitment For Clinical Trials

On July 7, 2011, the University of Alabama at Birmingham started recruiting patients for AREVA Med’s ²¹²Pb-TCMC-Trastuzumab radioimmunotherapy Phase I clinical trial using Lead-212 (212Pb).

Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments. This innovative approach, known as alpha radioimmunotherapy (RIT), was shown to specifically pinpoint and destroy cancer cells while limiting toxicity to healthy cells during preclinical studies.

This is the first clinical trial using medical-grade lead-212, and is designed for patients with HER-2 expressing carcinoma (e.g., ovarian, pancreatic, peritoneal, colon, gastric, or breast), mainly confined to the abdominal cavity.  For details concerning this clinical trial, visit: http://clinicaltrials.gov/ct2/show/NCT01384253

Currently, cancer in the abdominal cavity can be challenging to cure with standard therapies, such as chemotherapy, immunotherapy, and palliative care. The Alpha RIT treatment using AREVA’s lead-212 isotope is designed to address this unmet medical need.

Alpha RIT works by binding an isotope, such as lead-212, to an antibody. Using the body’s own antigens as ID tags on the individual neoplasm cancer cells, the antibodies with the isotopes individually connect with the cancer cells and destroy them. Watch the video showing this process.

In nuclear medicine, the development of new treatments is dictated by isotope availability. After years of research and development, AREVA created a process for extracting lead-212 isotopes from thorium derived from its industrial nuclear activities.

As announced in an earlier post, production of medical-grade lead-212 by AREVA Med, an AREVA subsidiary, will be conducted in the new Maurice Tubiana laboratory now under construction at Bessines-sur-Gartempe in the Limousin region of France.

May 31, 2011 | 4:53 pm

AREVA anti-cancer nuclear medicine laboratory under construction

You may not often put the two words “nuclear” and “medicine” together, but AREVA has, and opened a new front in the battle against cancer with the innovation and development of a promising treatment using Lead-212, a byproduct of used nuclear fuel recycling.

Production of medical-grade Lead-212 by AREVA Med, an AREVA subsidiary, will be conducted in the new Maurice Tubiana laboratory now under construction at Bessines-sur-Gartempe in the Limousin region of France.

The laboratory, the only one of its kind in the world, is slated to begin production in 2013.

The laboratory’s construction follows authorization by American authorities in January 2011 to begin the first clinical trials of a new radioimmunotherapy (RIT) treatment with Lead-212 (watch the video).

Innovation in nuclear medicine is dependant on the availability of medical-grade isotopes. With the Maurice Tubiana laboratory, the reliable production of the rare Lead-212 isotope should make it possible to treat the most aggressive forms of cancer.


April 22, 2011 | 6:25 pm

AREVA Med Facility Nears Construction

In the battle against cancer, AREVA Med is glad to announce the “public hearing” period for the construction of AREVA Med’s new lead-212 isotopes production facility was successfully completed on March 15, 2011. We are now on the threshold of constructing this unique facility at AREVA’s Bessines site in the Limousin region of France.

AREVA Med, an AREVA subsidiary, is dedicated to developing medical grade lead-212 isotopes to be used in promising radioimmunotherapy (RIT). Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments.

In nuclear medicine, the development of new treatments is dictated by isotope availability. By utilizing AREVA’s engineering and technical expertise, in March 2010, AREVA Med announced the construction of a Lead-212 industrial production plant that will allow the creation of new targeted therapies for patients.

In August 2010, AREVA Med formed an Advisory Committee to provide strategic advice and scientific guidance in the field of Radioimmunotherapy.

January 24, 2011 | 5:51 pm

AREVA Receives Landmark Authorization to Initiate Clinical Trials for Promising Anticancer Treatment

AREVA announced today that its subsidiary AREVA Med, which specializes in nuclear medicine, has received authorization from the Food and Drug Administration (FDA) to begin U.S. clinical trials for a new treatment aimed at combating cancer. This is the first such authorization for clinical trials using the lead-212 isotope worldwide.

AREVA has developed a process for extracting lead-212 from thorium derived from its industrial activities. Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments. This innovative approach, known as alpha radio-immunotherapy, specifically pinpoints and destroys cancer cells while limiting toxicity to healthy cells.

Phase I* clinical trials will begin this year in the United States and will take approximately two years to complete.

“Nuclear energy and nuclear medicine are technology- and capital-intensive disciplines that have strong historical links. AREVA is a forward-thinking company, and our investment in AREVA Med is one of many aimed at developing innovative solutions that improve people’s lives. This landmark FDA authorization is a very important step that could lead to a potential treatment for very aggressive and lethal cancers,” said Jacques Besnainou, CEO of AREVA North America.

“This decisive FDA authorization brings us much closer to our ultimate goal – creating innovative treatments to combat cancer. This authorization represents a major recognition of the expertise and commitment of AREVA’s team and that of our top-notch scientific partners,” said Patrick Bourdet, President and CEO of AREVA Med.

In nuclear medicine, the development of new treatments is constrained by the availability of isotopes. AREVA announced in 2010 the construction of a facility to produce lead-212 in the Limousin region of France, which would facilitate the creation of new treatments for patients.

For more information, please visit: www.areva.com and www.arevamed.com.

*A Phase I clinical trial primarily aims at confirming the safety of treatments in patients.

August 26, 2010 | 9:17 am

Advisory Committee to Support AREVA Med Developments


Bringing industry and medicine together in the battle against cancer, AREVA Med has announced another important milestone to continue this fight.

AREVA Med, an AREVA subsidiary, is dedicated to developing medical grade lead-212 isotopes to be used in promising Radioimmunotherapy. Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments.

In nuclear medicine, the development of new treatments is dictated by isotope availability. By utilizing AREVA’s engineering and technical expertise, in March 2010, AREVA Med announced the construction of a Lead-212 industrial production plant that will allow the creation of new targeted therapies for patients. 


Now, to support the project’s rapid development, AREVA Med has formed an Advisory Committee to provide strategic advice and scientific guidance in the field of Radioimmunotherapy.
read more…

April 13, 2010 | 5:19 pm

AREVA Med: New Research Agreement with University of Cincinnati

AREVA subsidiary AREVA Med and the University of Cincinnati, Ohio, announced today that they have signed a research agreement to develop a new treatment to combat cancer. Under the agreement, AREVA will provide the medical-grade isotope Lead-212 to the university for researchers to conduct studies on alpha radio-immunotherapy which uses this isotope to treat prostate cancer.

AREVA Med

Already the use of AREVA’s medical-grade Lead-212 isotope has proved promising in research efforts. Over the past few years, AREVA and its partners have demonstrated significant benefits by using Lead-212 as an innovative type of nuclear medicine to combat cancer.

Because Lead-212 is a rare isotope, AREVA has utilized is experience in radiochemistry and nuclear engineering to develop a new process to produce Lead-212 so that it can be used for this type of research.

More information on the AREVA Med project is available here or read the press release.

March 10, 2010 | 5:04 pm

AREVA to Build Facility for Medical Isotope Production

AREVA Med, an AREVA subsidiary, announced today the future construction of a facility in France that will produce on a large-scale medical grade lead 212.

Why Lead-212?

Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments. Over the past few years, AREVA Med and its partners demonstrated the benefits of Lead-212 for use in innovative alpha radio-immunotherapy to combat cancer.

What does AREVA know about nuclear medicine?

By relying on its experience in radiochemistry and nuclear engineering, AREVA has developed innovative processes to extract rare isotopes derived from its industrial activities.

Why is AREVA building a facility to produce large quantities of Lead-212?

In nuclear medicine, the development of new treatments is dictated by isotope availability. With this new facility scheduled to open in 2013, rare Lead-212 will become more widely available and allow for the creation of new targeted therapies for patients.

Check out the press release and other blogs on this exciting project

November 10, 2009 | 1:30 pm

A Look at AREVA’s Work for the Advancement of Nuclear Medicine

by Katherine Berezowskyj

Last week France’s TF1 television network featured AREVA’s innovative work under way in partnership with the U.S. National Cancer Institute and the University of Alabama for the development of a treatment to fight cancer.

The news team got to take a look inside AREVA’s La Hague Facility, in Normandy, where the idea of using AREVA’s expertise in nuclear engineering first came into being. The piece from TF1 also shows the important research and clinical testing underway with partners in the United States.

The clip is a great overview of this project, but unfortunately it’s in French. For those of you who are not fluent, there’s a cheat-sheet with a translation of the video right here (PDF).

AREVA Med, an AREVA subsidiary, is developing innovative methods for the production of the Lead-212 radio-isotope. This isotope has shown to be very promising in tests when used in the targeting therapy called Alpha radio-immunotherapy (Alpha-RIT). Alpha-RIT is a very powerful anti-cancer therapy that works by binding an isotope, like Lead-212, to a monoclonal antibody. Using the body’s own antigens, this treatment targets only cancer cells and destroys them using the high energy of Lead-212. While Alpha-RIT has potential to treat numerous types of cancers, including those that don’t respond well to chemotherapy or radiation, these radio-isotopes have traditionally existed in very limited quantities, hindering the development of new scientific treatments. This is why AREVA has focused on an isotope production method, to make sure Lead-212 is available for cancer research and future treatments.

September 25, 2009 | 1:44 pm

AREVA Med CEO Interview

And if the AREVA Med recognition at the CGI event has you curious for more background on this effort, do see the interview with CEO Patrick Bourdet here:

http://djysrv.blogspot.com/2009/05/areva-enters-nuclear-medicine-market.html